BABAK MEDICAL LIMITED


2022-05-112023-05-312023-05-31false14101884BABAK MEDICAL LIMITED2023-10-2686220iso4217:GBPxbrli:pure141018842022-05-11141018842023-05-31141018842022-05-112023-05-31141018842022-05-10141018842022-05-10141018842022-05-102022-05-1014101884bus:SmallEntities2022-05-112023-05-3114101884bus:AuditExempt-NoAccountantsReport2022-05-112023-05-3114101884bus:AbridgedAccounts2022-05-112023-05-3114101884bus:PrivateLimitedCompanyLtd2022-05-112023-05-3114101884core:WithinOneYear2023-05-3114101884core:AfterOneYear2023-05-3114101884core:WithinOneYear2022-05-1014101884core:AfterOneYear2022-05-1014101884core:ShareCapital2023-05-3114101884core:SharePremium2023-05-3114101884core:RevaluationReserve2023-05-3114101884core:OtherReservesSubtotal2023-05-3114101884core:RetainedEarningsAccumulatedLosses2023-05-3114101884core:ShareCapital2022-05-1014101884core:SharePremium2022-05-1014101884core:RevaluationReserve2022-05-1014101884core:OtherReservesSubtotal2022-05-1014101884core:RetainedEarningsAccumulatedLosses2022-05-1014101884core:LandBuildings2023-05-3114101884core:PlantMachinery2023-05-3114101884core:Vehicles2023-05-3114101884core:FurnitureFittings2023-05-3114101884core:OfficeEquipment2023-05-3114101884core:NetGoodwill2023-05-3114101884core:IntangibleAssetsOtherThanGoodwill2023-05-3114101884core:ListedExchangeTraded2023-05-3114101884core:UnlistedNon-exchangeTraded2023-05-3114101884core:LandBuildings2022-05-1014101884core:PlantMachinery2022-05-1014101884core:Vehicles2022-05-1014101884core:FurnitureFittings2022-05-1014101884core:OfficeEquipment2022-05-1014101884core:NetGoodwill2022-05-1014101884core:IntangibleAssetsOtherThanGoodwill2022-05-1014101884core:ListedExchangeTraded2022-05-1014101884core:UnlistedNon-exchangeTraded2022-05-1014101884core:LandBuildings2022-05-112023-05-3114101884core:PlantMachinery2022-05-112023-05-3114101884core:Vehicles2022-05-112023-05-3114101884core:FurnitureFittings2022-05-112023-05-3114101884core:OfficeEquipment2022-05-112023-05-3114101884core:NetGoodwill2022-05-112023-05-3114101884core:IntangibleAssetsOtherThanGoodwill2022-05-112023-05-3114101884core:ListedExchangeTraded2022-05-112023-05-3114101884core:UnlistedNon-exchangeTraded2022-05-112023-05-3114101884core:MoreThanFiveYears2022-05-112023-05-3114101884core:Non-currentFinancialInstruments2023-05-3114101884core:Non-currentFinancialInstruments2022-05-1014101884dpl:CostSales2022-05-112023-05-3114101884dpl:DistributionCosts2022-05-112023-05-3114101884core:LandBuildings2022-05-112023-05-3114101884core:PlantMachinery2022-05-112023-05-3114101884core:Vehicles2022-05-112023-05-3114101884core:FurnitureFittings2022-05-112023-05-3114101884core:OfficeEquipment2022-05-112023-05-3114101884dpl:AdministrativeExpenses2022-05-112023-05-3114101884core:NetGoodwill2022-05-112023-05-3114101884core:IntangibleAssetsOtherThanGoodwill2022-05-112023-05-3114101884dpl:GroupUndertakings2022-05-112023-05-3114101884dpl:ParticipatingInterests2022-05-112023-05-3114101884dpl:GroupUndertakingscore:ListedExchangeTraded2022-05-112023-05-3114101884core:ListedExchangeTraded2022-05-112023-05-3114101884dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-05-112023-05-3114101884core:UnlistedNon-exchangeTraded2022-05-112023-05-3114101884dpl:CostSales2022-05-102022-05-1014101884dpl:DistributionCosts2022-05-102022-05-1014101884core:LandBuildings2022-05-102022-05-1014101884core:PlantMachinery2022-05-102022-05-1014101884core:Vehicles2022-05-102022-05-1014101884core:FurnitureFittings2022-05-102022-05-1014101884core:OfficeEquipment2022-05-102022-05-1014101884dpl:AdministrativeExpenses2022-05-102022-05-1014101884core:NetGoodwill2022-05-102022-05-1014101884core:IntangibleAssetsOtherThanGoodwill2022-05-102022-05-1014101884dpl:GroupUndertakings2022-05-102022-05-1014101884dpl:ParticipatingInterests2022-05-102022-05-1014101884dpl:GroupUndertakingscore:ListedExchangeTraded2022-05-102022-05-1014101884core:ListedExchangeTraded2022-05-102022-05-1014101884dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-05-102022-05-1014101884core:UnlistedNon-exchangeTraded2022-05-102022-05-1014101884core:NetGoodwill2023-05-3114101884core:IntangibleAssetsOtherThanGoodwill2023-05-3114101884core:LandBuildings2023-05-3114101884core:PlantMachinery2023-05-3114101884core:Vehicles2023-05-3114101884core:FurnitureFittings2023-05-3114101884core:OfficeEquipment2023-05-3114101884core:AfterOneYear2023-05-3114101884core:WithinOneYear2023-05-3114101884core:ListedExchangeTraded2023-05-3114101884core:UnlistedNon-exchangeTraded2023-05-3114101884core:ShareCapital2023-05-3114101884core:SharePremium2023-05-3114101884core:RevaluationReserve2023-05-3114101884core:OtherReservesSubtotal2023-05-3114101884core:RetainedEarningsAccumulatedLosses2023-05-3114101884core:NetGoodwill2022-05-1014101884core:IntangibleAssetsOtherThanGoodwill2022-05-1014101884core:LandBuildings2022-05-1014101884core:PlantMachinery2022-05-1014101884core:Vehicles2022-05-1014101884core:FurnitureFittings2022-05-1014101884core:OfficeEquipment2022-05-1014101884core:AfterOneYear2022-05-1014101884core:WithinOneYear2022-05-1014101884core:ListedExchangeTraded2022-05-1014101884core:UnlistedNon-exchangeTraded2022-05-1014101884core:ShareCapital2022-05-1014101884core:SharePremium2022-05-1014101884core:RevaluationReserve2022-05-1014101884core:OtherReservesSubtotal2022-05-1014101884core:RetainedEarningsAccumulatedLosses2022-05-1014101884core:NetGoodwill2022-05-1014101884core:IntangibleAssetsOtherThanGoodwill2022-05-1014101884core:LandBuildings2022-05-1014101884core:PlantMachinery2022-05-1014101884core:Vehicles2022-05-1014101884core:FurnitureFittings2022-05-1014101884core:OfficeEquipment2022-05-1014101884core:AfterOneYear2022-05-1014101884core:WithinOneYear2022-05-1014101884core:ListedExchangeTraded2022-05-1014101884core:UnlistedNon-exchangeTraded2022-05-1014101884core:ShareCapital2022-05-1014101884core:SharePremium2022-05-1014101884core:RevaluationReserve2022-05-1014101884core:OtherReservesSubtotal2022-05-1014101884core:RetainedEarningsAccumulatedLosses2022-05-1014101884core:AfterOneYear2022-05-112023-05-3114101884core:WithinOneYear2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:CostValuation2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-05-112023-05-3114101884core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3114101884core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3114101884core:Non-currentFinancialInstrumentscore:CostValuation2022-05-1014101884core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-05-1014101884core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-05-1014101884bus:Director12022-05-112023-05-31

BABAK MEDICAL LIMITED

Registered Number
14101884
(England and Wales)

Unaudited Financial Statements for the Period ended
31 May 2023

BABAK MEDICAL LIMITED
Company Information
for the period from 11 May 2022 to 31 May 2023

Director

DANESHMAND, Babak

Registered Address

8b Accommodation Road
Golders Green
London
NW11 8ED

Registered Number

14101884 (England and Wales)
BABAK MEDICAL LIMITED
Statement of Financial Position
31 May 2023

Notes

2023

£

£

Fixed assets
Tangible assets52,648
2,648
Current assets
Cash at bank and on hand78,501
78,501
Creditors amounts falling due within one year(63,330)
Net current assets (liabilities)15,171
Total assets less current liabilities17,819
Net assets17,819
Capital and reserves
Called up share capital100
Profit and loss account17,719
Shareholders' funds17,819
  • The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
  • The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  • The Director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  • These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.
  • The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved and authorised for issue by the Director on 26 October 2023, and are signed on its behalf by:
DANESHMAND, Babak
Director
Registered Company No. 14101884
BABAK MEDICAL LIMITED
Notes to the Financial Statements
for the period ended 31 May 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
4.Employee information

2023
Average number of employees during the year1
5.Property, plant and equipment

Total

£
Cost or valuation
Additions3,531
At 31 May 233,531
Depreciation and impairment
Charge for year883
At 31 May 23883
Net book value
At 31 May 232,648
At 10 May 22-